COMPANY

Akari Therapeutics

HQ: Tampa, FL source · akaritx.com ↗ · Southeast

Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. From company website Source · Oct 13, 2026

Keywords: molecule aktx ceacam5

Profile checked Oct 10, 2026

$13.0MRaised (2 yrs)

Timeline

May 21, 2026 Raise Private placement: $5.5M (total, as published), announced May 21, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Jun 3, 2026 SEC Form D ↗
Dec 16, 2025 Raise Follow-on offering — Registered direct: $5M (total, as published), announced Dec 16, 2025. Source: SEC filing. source ↗
Oct 15, 2025 Raise Follow-on offering — Registered direct: $2.5M (total, as published), announced Oct 15, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 24, 2025 SEC Form D ↗

Funding

Raised: $13.0M. Last 2 years.

May 21, 2026 Private placement: $5.5M (total, as published), announced May 21, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Jun 3, 2026 SEC Form D ↗
Dec 16, 2025 Follow-on offering — Registered direct: $5M (total, as published), announced Dec 16, 2025. Source: SEC filing. source ↗
Oct 15, 2025 Follow-on offering — Registered direct: $2.5M (total, as published), announced Oct 15, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 24, 2025 SEC Form D ↗

Connect

Contact page